KR100810930B1 - 나테글리니드 ｂ형 결정의 제조방법 - Google Patents

나테글리니드 ｂ형 결정의 제조방법 Download PDF

Info

Publication number
KR100810930B1
KR100810930B1 KR1020037005671A KR20037005671A KR100810930B1 KR 100810930 B1 KR100810930 B1 KR 100810930B1 KR 1020037005671 A KR1020037005671 A KR 1020037005671A KR 20037005671 A KR20037005671 A KR 20037005671A KR 100810930 B1 KR100810930 B1 KR 100810930B1
Authority
KR
South Korea
Prior art keywords
nateglinide
crystal
crystals
producing
type
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
KR1020037005671A
Other languages
English (en)
Korean (ko)
Other versions
KR20030059212A (ko
Inventor
스미카와미치토
마루오마코토
미야자키가즈오
니시나시게히로
마쓰자와유키코
Original Assignee
아지노모토 가부시키가이샤
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 아지노모토 가부시키가이샤 filed Critical 아지노모토 가부시키가이샤
Publication of KR20030059212A publication Critical patent/KR20030059212A/ko
Application granted granted Critical
Publication of KR100810930B1 publication Critical patent/KR100810930B1/ko
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C227/00—Preparation of compounds containing amino and carboxyl groups bound to the same carbon skeleton
    • C07C227/38—Separation; Purification; Stabilisation; Use of additives
    • C07C227/40—Separation; Purification
    • C07C227/42—Crystallisation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C231/00—Preparation of carboxylic acid amides
    • C07C231/22—Separation; Purification; Stabilisation; Use of additives
    • C07C231/24—Separation; Purification
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/12—Systems containing only non-condensed rings with a six-membered ring
    • C07C2601/14—The ring being saturated

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Diabetes (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Emergency Medicine (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Endocrinology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
KR1020037005671A 2000-10-24 2001-10-23 나테글리니드 ｂ형 결정의 제조방법 Expired - Fee Related KR100810930B1 (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2000324375 2000-10-24
JPJP-P-2000-00324375 2000-10-24
PCT/JP2001/009293 WO2002034713A1 (en) 2000-10-24 2001-10-23 Process for producing b-form nateglinide crystal

Publications (2)

Publication Number Publication Date
KR20030059212A KR20030059212A (ko) 2003-07-07
KR100810930B1 true KR100810930B1 (ko) 2008-03-10

Family

ID=18801920

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020037005671A Expired - Fee Related KR100810930B1 (ko) 2000-10-24 2001-10-23 나테글리니드 ｂ형 결정의 제조방법

Country Status (18)

Country Link
US (2) US20030229249A1 (enExample)
EP (1) EP1334964B1 (enExample)
JP (1) JP4225057B2 (enExample)
KR (1) KR100810930B1 (enExample)
CN (1) CN100422143C (enExample)
AT (1) ATE370115T1 (enExample)
AU (1) AU2001296001A1 (enExample)
BR (1) BR0114846A (enExample)
CA (1) CA2426745C (enExample)
CY (1) CY1106839T1 (enExample)
DE (1) DE60130014T2 (enExample)
DK (1) DK1334964T3 (enExample)
ES (1) ES2288997T3 (enExample)
MX (1) MXPA03003575A (enExample)
PT (1) PT1334964E (enExample)
RU (1) RU2275354C2 (enExample)
TW (1) TWI293290B (enExample)
WO (1) WO2002034713A1 (enExample)

Families Citing this family (73)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ521366A (en) * 2000-03-17 2005-07-29 Ajinomoto Kk Drugs for complications of diabetes and neuropathy, and utilisation thereof
KR100819358B1 (ko) * 2000-10-18 2008-04-04 아지노모토 가부시키가이샤 나테글리니드 결정의 제조방법
DK1334962T3 (da) * 2000-10-18 2007-12-10 Ajinomoto Kk Fremgangsmåder til fremstilling af acylphenylalanin
JPWO2002040010A1 (ja) * 2000-10-24 2004-06-03 味の素株式会社 ナテグリニド含有親水性医薬製剤
CA2426263C (en) * 2000-10-24 2010-05-25 Ajinomoto Co., Inc. Nateglinide-containing preparation
US7411089B2 (en) 2002-04-15 2008-08-12 Ajinomoto Co., Inc. Nateglinide crystals
AU2003236243A1 (en) * 2002-04-15 2003-10-27 Ajinomoto Co., Inc. Novel nateglinide crystal
US6861553B2 (en) 2002-07-03 2005-03-01 Teva Pharmaceuticals Industries Ltd. Process for preparing nateglinide and intermediates thereof
US7420084B2 (en) * 2002-07-18 2008-09-02 Teva Pharmaceutical Industries Ltd. Polymorphic forms of nateglinide
US7534913B2 (en) 2002-07-18 2009-05-19 Teva Pharmaceutica Industries Ltd. Crystalline form of nateglinide
JP2006511614A (ja) * 2002-07-18 2006-04-06 テバ ファーマシューティカル インダストリーズ リミティド ナテグリニドの多形性形状
US7148376B2 (en) 2002-07-18 2006-12-12 Teva Pharmaceutical Industries Ltd. Polymorphic forms of nateglinide
US7358390B2 (en) 2002-07-18 2008-04-15 Teva Pharmaceutical Industries Ltd. Polymorphic forms of nateglinide
ES2279921T3 (es) * 2003-11-26 2007-09-01 A.M.S.A. Anonima Materie Sintetiche E Affini S.P.A. Procedimiento para la preparacion de nateglinida preferentemente en forma b.
KR20070009726A (ko) * 2004-05-07 2007-01-18 테바 파마슈티컬 인더스트리즈 리미티드 나테글리나이드의 다형태
WO2005110395A1 (en) * 2004-05-19 2005-11-24 University Of South Carolina System and device for magnetic drug targeting with magnetic drug carrier particles
US20080096970A1 (en) * 2004-05-20 2008-04-24 Sundaram Venkataraman Stable Nateglinide Form B Compositions
US7425648B2 (en) 2005-01-03 2008-09-16 A.M.S.A. Anonima Materie Sintetiche E. Affini S.P.A. Process for the preparation of nateglinide, preferably in B-form
KR20070102694A (ko) * 2005-01-31 2007-10-19 아지노모토 가부시키가이샤 혈당 강하제를 함유하는, 내당능 이상, 경계형 당뇨병,인슐린 저항성 및 고인슐린혈증 개선 또는 치료용 의약조성물
WO2007135533A1 (en) * 2006-05-23 2007-11-29 Aurobindo Pharma Limited Process for preparing nateglinide b-type crystals
KR100837843B1 (ko) * 2006-12-26 2008-06-13 씨제이제일제당 (주) 나테글리나이드 결정형, 그 제조방법, 및 그를 포함하는약제학적 조성물
EP2580188A1 (en) 2010-06-14 2013-04-17 Cilpa Limited A process for the preparation of nateglinide
WO2014037832A2 (en) 2012-09-06 2014-03-13 Mahesh Kandula Compositions and methods for the treatment of epilepsy and neurological diseases
CA2873093A1 (en) 2012-05-07 2013-11-14 Cellixbio Private Limited Compositions and methods for treatment of neuromuscular disorders and neurodegenerative disorders
WO2013167990A1 (en) 2012-05-07 2013-11-14 Mahesh Kandula Compositions and methods for the treatment of depression
SG11201407300VA (en) 2012-05-07 2014-12-30 Cellix Bio Private Ltd Compositions and methods for the treatment of neurological disorders
US9266823B2 (en) 2012-05-08 2016-02-23 Cellix Bio Private Limited Compositions and methods for the treatment of parkinson's disease
US9403826B2 (en) 2012-05-08 2016-08-02 Cellix Bio Private Limited Compositions and methods for the treatment of inflammatory disorders
WO2013168025A1 (en) 2012-05-08 2013-11-14 Mahesh Kandula Compositions and methods for treatment of blood clotting disorders
US9434704B2 (en) 2012-05-08 2016-09-06 Cellix Bio Private Limited Compositions and methods for the treatment of neurological degenerative disorders
WO2013167987A1 (en) * 2012-05-08 2013-11-14 Mahesh Kandula Compositions and methods for the treatment of diabetes
WO2013167991A1 (en) 2012-05-08 2013-11-14 Mahesh Kandula Compositions and methods for the treatment of metabolic disorders
WO2013168014A1 (en) 2012-05-10 2013-11-14 Mahesh Kandula Compositions and methods for the treatment of familial amyloid polyneuropathy
US9339484B2 (en) 2012-05-10 2016-05-17 Cellix Bio Private Limited Compositions and methods for the treatment of restless leg syndrome and fibromyalgia
WO2013168011A1 (en) 2012-05-10 2013-11-14 Mahesh Kandula Compositions and methods for the treatment of chronic pain
US9573927B2 (en) 2012-05-10 2017-02-21 Cellix Bio Private Limited Compositions and methods for the treatment of severe pain
WO2013167999A2 (en) 2012-05-10 2013-11-14 Mahesh Kandula Compositions and methods for the treatment of neurologic diseases
US9346742B2 (en) 2012-05-10 2016-05-24 Cellix Bio Private Limited Compositions and methods for the treatment of fibromyalgia pain
WO2013168001A1 (en) 2012-05-10 2013-11-14 Mahesh Kandula Compositions and methods for the treatment of moderate to severe pain
WO2013168033A1 (en) 2012-05-10 2013-11-14 Mahesh Kandula Compositions and methods for treatment of neurologic diseases
SG11201407318UA (en) 2012-05-10 2014-12-30 Cellix Bio Private Ltd Compositions and methods for the treatment of metabolic syndrome
WO2013168002A1 (en) 2012-05-10 2013-11-14 Mahesh Kandula Compositions and methods for the treatment of neurological conditions
US9315478B2 (en) 2012-05-10 2016-04-19 Cellix Bio Private Limited Compositions and methods for the treatment of metabolic syndrome
WO2013168015A1 (en) 2012-05-10 2013-11-14 Mahesh Kandula Compositions and methods for the treatment of asthma and allergy
US9242939B2 (en) 2012-05-10 2016-01-26 Cellix Bio Private Limited Compositions and methods for the treatment of respiratory disorders
AU2013264820A1 (en) 2012-05-23 2014-11-27 Cellixbio Private Limited Compositions and methods for treatment of mucositis
WO2013175357A2 (en) 2012-05-23 2013-11-28 Mahesh Kandula Compositions and methods for the treatment of inflammatory bowel disease
US9227974B2 (en) 2012-05-23 2016-01-05 Cellex Bio Private Limited Compositions and methods for the treatment of respiratory disorders
US9492409B2 (en) 2012-05-23 2016-11-15 Cellix Bio Private Limited Compositions and methods for the treatment of local pain
AU2013264896A1 (en) 2012-05-23 2014-11-27 Cellixbio Private Limited Compositions and methods for the treatment of multiple sclerosis
US9434729B2 (en) 2012-05-23 2016-09-06 Cellix Bio Private Limited Compositions and methods for the treatment of periodontitis and rheumatoid arthritis
US9108942B1 (en) 2014-11-05 2015-08-18 Mahesh Kandula Compositions and methods for the treatment of moderate to severe pain
WO2014020480A2 (en) 2012-08-03 2014-02-06 Mahesh Kandula Compositions and methods for the treatment migraine and neurologic diseases
US9624168B2 (en) 2012-09-06 2017-04-18 Cellix Bio Private Limited Compositions and methods for the treatment inflammation and lipid disorders
CA2873029A1 (en) 2012-09-08 2014-03-13 Cellixbio Private Limited Compositions and methods for the treatment of inflammation and lipid disorders
US9333187B1 (en) 2013-05-15 2016-05-10 Cellix Bio Private Limited Compositions and methods for the treatment of inflammatory bowel disease
CA2914461A1 (en) 2013-06-04 2014-12-11 Cellixbio Private Limited Compositions and methods for the treatment of diabetes and pre-diabetes
US9096537B1 (en) 2014-12-31 2015-08-04 Mahesh Kandula Compositions and methods for the treatment of mucositis
EP3240779B1 (en) 2014-09-26 2020-10-28 Cellixbio Private Limited Compositions and methods for the treatment of epilepsy and neurological disorders
CN107207403A (zh) 2014-09-29 2017-09-26 塞尔利克斯生物私人有限公司 用于治疗多发性硬化的组合物和方法
EP3212626B1 (en) 2014-10-27 2018-11-07 Cellix Bio Private Limited Three component salts of fumaric acid monomethyl ester with piperazine or ethylene diamine for the treatment of multiple sclerosis
US9284287B1 (en) 2014-11-05 2016-03-15 Cellix Bio Private Limited Compositions and methods for the suppression of carbonic anhydrase activity
US9321716B1 (en) 2014-11-05 2016-04-26 Cellix Bio Private Limited Compositions and methods for the treatment of metabolic syndrome
US10208014B2 (en) 2014-11-05 2019-02-19 Cellix Bio Private Limited Compositions and methods for the treatment of neurological disorders
US9173877B1 (en) 2014-11-05 2015-11-03 Cellix Bio Private Limited Compositions and methods for the treatment of local pain
US9290486B1 (en) 2014-11-05 2016-03-22 Cellix Bio Private Limited Compositions and methods for the treatment of epilepsy
US9150557B1 (en) 2014-11-05 2015-10-06 Cellix Bio Private Limited Compositions and methods for the treatment of hyperglycemia
US9175008B1 (en) 2014-11-05 2015-11-03 Cellix Bio Private Limited Prodrugs of anti-platelet agents
CN104402756B (zh) * 2014-11-27 2016-08-31 天方药业有限公司 一种高纯度那格列奈的制备方法
US9932294B2 (en) 2014-12-01 2018-04-03 Cellix Bio Private Limited Compositions and methods for the treatment of multiple sclerosis
US9206111B1 (en) 2014-12-17 2015-12-08 Cellix Bio Private Limited Compositions and methods for the treatment of neurological diseases
CN110845355A (zh) 2015-01-06 2020-02-28 塞尔利克斯生物私人有限公司 用于治疗炎症和疼痛的组合物和方法
CN109369443A (zh) * 2018-11-05 2019-02-22 扬子江药业集团江苏海慈生物药业有限公司 一种新的那格列奈h晶型的制备方法

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5463116A (en) 1991-07-30 1995-10-31 Ajinomoto Co., Inc. Crystals of N- (trans-4-isopropylcyclohexlycarbonyl)-D-phenylalanine and methods for preparing them

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS6354321A (ja) * 1985-03-27 1988-03-08 Ajinomoto Co Inc 血糖降下剤
AU615966B2 (en) * 1987-12-04 1991-10-17 Takeda Chemical Industries Ltd. Crystals of cephem hydrochloride
ATE149483T1 (de) * 1991-07-30 1997-03-15 Ajinomoto Kk Kristalle von n-(trans-4- isopropylcyclohexylcarbonyl)-d-phenylalanin und verfahren zu ihrer herstellung
DE69740161D1 (de) * 1996-11-15 2011-05-12 Ajinomoto Kk Nateglinide-Tablettenzubereitungen
US6844006B1 (en) * 1999-07-09 2005-01-18 Pennfield Oil Company Process and apparatus for the preparation of chlortetracycline-containing animal feed compositions
EP1616561B1 (en) * 1999-12-28 2008-06-25 Ajinomoto Co., Inc. Antidiabetic preparation for oral administration
NZ521366A (en) * 2000-03-17 2005-07-29 Ajinomoto Kk Drugs for complications of diabetes and neuropathy, and utilisation thereof
KR100819358B1 (ko) * 2000-10-18 2008-04-04 아지노모토 가부시키가이샤 나테글리니드 결정의 제조방법
DK1334962T3 (da) * 2000-10-18 2007-12-10 Ajinomoto Kk Fremgangsmåder til fremstilling af acylphenylalanin
CA2426263C (en) * 2000-10-24 2010-05-25 Ajinomoto Co., Inc. Nateglinide-containing preparation
US7411089B2 (en) * 2002-04-15 2008-08-12 Ajinomoto Co., Inc. Nateglinide crystals

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5463116A (en) 1991-07-30 1995-10-31 Ajinomoto Co., Inc. Crystals of N- (trans-4-isopropylcyclohexlycarbonyl)-D-phenylalanine and methods for preparing them

Also Published As

Publication number Publication date
CY1106839T1 (el) 2012-05-23
US7544834B2 (en) 2009-06-09
JPWO2002034713A1 (ja) 2004-03-04
WO2002034713A1 (en) 2002-05-02
MXPA03003575A (es) 2003-07-14
KR20030059212A (ko) 2003-07-07
CN100422143C (zh) 2008-10-01
AU2001296001A1 (en) 2002-05-06
ATE370115T1 (de) 2007-09-15
EP1334964A1 (en) 2003-08-13
ES2288997T3 (es) 2008-02-01
CN1483018A (zh) 2004-03-17
DK1334964T3 (da) 2007-09-24
RU2275354C2 (ru) 2006-04-27
EP1334964A4 (en) 2005-09-28
EP1334964B1 (en) 2007-08-15
JP4225057B2 (ja) 2009-02-18
BR0114846A (pt) 2004-02-25
DE60130014T2 (de) 2008-05-08
US20030229249A1 (en) 2003-12-11
CA2426745C (en) 2009-09-15
PT1334964E (pt) 2007-09-20
TWI293290B (enExample) 2008-02-11
US20070232829A1 (en) 2007-10-04
DE60130014D1 (de) 2007-09-27
CA2426745A1 (en) 2003-04-23

Similar Documents

Publication Publication Date Title
KR100810930B1 (ko) 나테글리니드 ｂ형 결정의 제조방법
US10273216B2 (en) Process for preparing crystalline methyl N- [2- [[[1-(4-chlorophenyl)-1H-pyrazol-3-yl]oxy]methyl]phenyl]-N-methoxycarbamate
TWI633109B (zh) 於製備式ｉ之吡啶并吡咯烯（ｐｙｒｉｐｙｒｏｐｅｎｅ）化合物之方法
JP2010508285A (ja) トリホスゲン（ｂｔｃ）を用いた糖の塩素化によるスクラロースの製造方法
EP0450684B1 (en) A process for the preparation of D-(-)-4-hydroxyphenylglycine and L-(+)-4-hydroxyphenylglycine, starting from D.L.-4-hydroxyphenylglycine
CA2479211A1 (en) 9-dexo-9a-aza-9a-methyl-9a-homoerythromycin a derivatives
US5493031A (en) N-hydroxysuccinimide monohydrate
US2456742A (en) Separation of isomers of amino acids
EP1098895B1 (fr) Procede pour la preparation du sel potassique du lintitript
NZ527138A (en) 3-(3-amidinophenyl)-5-[({[1-(1-(-iminoethyl)-4-piperidyl}amino)methyl]benzoic acid dihydrochloride and process for preparing the same
CN110256515A (zh) 多拉菌素晶型a、晶型b及其制备方法
JP3256376B2 (ja) トシル酸スプラタストの結晶およびその製造方法
WO2000027804A1 (en) Method for the crystallization of iopamidol
JPH06340599A (ja) 光学活性２−アミノ酪酸の製法
JP3316917B2 (ja) 新規フェニルアラニン塩結晶とその製造法
JP2949930B2 (ja) 光学活性１−フェニル−２−（ｐ−トリル）エチルアミンの精製方法
JPH1036350A (ja) ４−ヒドロキシピペリジンの精製方法
JPH0472824B2 (enExample)
JPH05503932A (ja) ７―クロル―キノリン―８―カルボン酸の精製方法
WO1997001563A1 (en) Stable bicozamycin benzoate crystals
JPH08295680A (ja) アミノチアゾール酢酸誘導体の製造方法
JPH0694435B2 (ja) （±）−シス−ペルメトリン酸の光学分割法
JPS60202706A (ja) 水分離剤
JPH0720915B2 (ja) （±）−トランス−ペルメトリン酸の光学分割法
JPS6072857A (ja) 高純度ｓ−カルボキシメチル−ｌ−システイン塩酸塩の製造法

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

R17-X000 Change to representative recorded

St.27 status event code: A-3-3-R10-R17-oth-X000

PN2301 Change of applicant

St.27 status event code: A-3-3-R10-R13-asn-PN2301

St.27 status event code: A-3-3-R10-R11-asn-PN2301

A201 Request for examination
P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

R17-X000 Change to representative recorded

St.27 status event code: A-3-3-R10-R17-oth-X000

R17-X000 Change to representative recorded

St.27 status event code: A-3-3-R10-R17-oth-X000

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

St.27 status event code: A-1-2-D10-D22-exm-PE0701

GRNT Written decision to grant
PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

St.27 status event code: A-2-2-U10-U12-oth-PR1002

Fee payment year number: 1

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 4

FPAY Annual fee payment

Payment date: 20120130

Year of fee payment: 5

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 5

FPAY Annual fee payment

Payment date: 20130201

Year of fee payment: 6

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 6

LAPS Lapse due to unpaid annual fee
PC1903 Unpaid annual fee

St.27 status event code: A-4-4-U10-U13-oth-PC1903

Not in force date: 20140301

Payment event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

PC1903 Unpaid annual fee

St.27 status event code: N-4-6-H10-H13-oth-PC1903

Ip right cessation event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

Not in force date: 20140301

R18-X000 Changes to party contact information recorded

St.27 status event code: A-5-5-R10-R18-oth-X000